CLEARWATER, FL – January 3, 2017 – Bovie Medical Corporation (NYSEMKT: BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that Robert L. Gershon, Chief Executive Officer of the Company, and Jack McCarthy, Chief Commercialization Officer, will participate in the 9th Annual Biotech Showcase Conference in San Francisco.

The conference will be held at the Hilton San Francisco Union Square in San Francisco, where Mr. Gershon will present to investors on Tuesday, January 10 at 11.00am PST, 2017. Mr. Gershon will discuss the Company and J-Plasma®, its transformational surgical product.

Mr. Gershon will also present at Medtech Showcase, which is part of the Biotech Showcase conference, on Wednesday, January 11 at 10.30am PST, at the Parc 55 San Francisco Hotel in Union Square.

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to and meet with investors and industry executives.

If you would like to schedule a one-on-one meeting with Bovie Medical management at the event, please register and proceed through the event’s partnering system or contact MBS Value Partners.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

Investor Relations:
MBS Value Partners
Lynn Morgen/ Jane Searle
212 750 5800
investor.relations@boviemed.com